Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

    September 21, 2023

    Liftoff for the Biotech Launch Pad

    September 20, 2023

    Five things: A biotech IPO, Shannon O’Brien suspension, life sciences philanthropy report

    September 19, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

      September 21, 2023

      Liftoff for the Biotech Launch Pad

      September 20, 2023

      Five things: A biotech IPO, Shannon O’Brien suspension, life sciences philanthropy report

      September 19, 2023

      Machine learning biotech raises $273 million in rare successful late-stage round

      September 15, 2023

      Discover the synergy between biotech, medtech and digital health in Ghent, a European technology capital

      September 14, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Bio Technology»Entact Bio Draws $81M Financing for Protein Enhancement Platform
    Bio Technology

    Entact Bio Draws $81M Financing for Protein Enhancement Platform

    yourbiotechBy yourbiotechDecember 7, 2022Updated:December 7, 2022No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Led by former Sanofi, Epizyme and Merck executive Victoria Richon, Entact Bio launched with $81 million Tuesday to advance its protein enhancement platform.

    The company will use the platform, dubbed Encompass, to develop enhancement-targeting chimeric (ENTAC) molecules. Rather than targeting proteins that cause or advance disease, Entact’s platform focuses on protecting beneficial proteins that help the body fight disease.

    Protein therapeutics are nothing new. A study released by Vision Research Reports five months ago found the protein therapeutics market was valued at $284.5 billion in 2021 and is predicted to surpass $566.82 billion by 2030.

    Protein enhancement, however, is less common. One of the better-known protein enhancement therapies is Vertex Pharmaceuticals’ cystic fibrosis treatment Trikafta, which enhances the function of the F508del-CFTR protein at the cell surface.

    But unlike Vertex’s therapy, Entact’s platform utilizes deubiquitinases, or DUBs–enzymes that regulate proteins in cells. The company stated ENTACs “bring together beneficial target proteins with DUBs.” The DUBs then shorten or remove chains of ubiquitin attached to the target protein, enhancing its function and restoring the cell back to health.

    DUBs can be recruited when there is not enough of the target protein and when it’s in the wrong place in the cell or is not working properly.

    David Komander, Ph.D., a professor and head of WEHI’s ubiquitin signaling division, said in the press release that many think of ubiquitin as a “molecule that directs proteins to the cellular garbage bin,” as one of its primary functions is marking proteins for degradation.

    “We now know that ubiquitin also has the ability to change protein function, including activation, localization and interaction through exquisite regulation by DUBs and other enzymes,” he added.

    The Series A financing was led by Qiming Venture Partners USA and venBio Partners, with participation from Abingworth, Citadel’s Surveyor Capital and 4BIO Capital.

    As for which therapeutic areas the company plans to target, Richon told BioSpace, “While we’re not talking publicly about our pipeline yet, in almost every disease, enhancing the function of beneficial proteins could make an impact.”

    Richon also explained the company’s goals. In the short term, the team is focused on building a “really effective drug discovery team that’s strong not only in terms of capabilities and background but also in diversity.” And in the long term, the team will continue to advance the Encompass platform.

    “Ultimately, our goal is to bring innovative medications forward to help patients who currently have too few options,” Richon said. “These ENTAC medicines will make an important difference for patients whose needs aren’t adequately met by today’s treatments.”

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleJanssen Bows Out as Contender for Horizon Therapeutics Buyout
    Next Article Biotech veteran Jeff Jonas on leaving Sage, guiding new biotechs and his ‘personal odyssey’
    yourbiotech
    • Website

    Related Posts

    Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference

    September 21, 2023

    Liftoff for the Biotech Launch Pad

    September 20, 2023

    Five things: A biotech IPO, Shannon O’Brien suspension, life sciences philanthropy report

    September 19, 2023

    Machine learning biotech raises $273 million in rare successful late-stage round

    September 15, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.